bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026
bioAffinity Technologies will sponsor a Learning Theater presentation at CHEST 2026 on October 21, hosted by CMO Dr. Gordon Downie, on using CyPath Lung for lung cancer risk stratification and pulmonary nodule management. The presentation will include preliminary research data on an investigational test for asthma and COPD-related lung inflammation, which is not yet available for clinical use.
Key figures
- Clinical trial npv
- 99%
- Clinical trial accuracy
- 88%
- Clinical trial sensitivity
- 92%
- Clinical trial specificity
- 87%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.